Voyager Therapeutics, Inc.
Voyager Therapeutics is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, aiming to create disease-modifying neurogenetic medicines for neurological diseases such as Alzheimer’s, ALS, Parkinson’s, and others. Their mission is to identify validated targets, advance multiple therapeutic modalities, and deliver treatments to the right areas within the central nervous system, with a vision of making transformative treatments and cures available to millions affected by neurological diseases.
Industries
Nr. of Employees
medium (51-250)
Voyager Therapeutics, Inc.
Patents
Frataxin expression constructs having engineered promoters and methods of use thereof
US-12281321-B2
View Details
Frataxin expression constructs having engineered promoters and methods of use thereof
US-12281321-B2
View DetailsProducts
Anti-tau antibody therapy for Alzheimer’s disease (development candidate)
Preclinical and IND-enabling development of an anti-tau biologic intended to modify disease processes in Alzheimer’s disease.
Tau-targeting siRNA gene therapy for Alzheimer’s disease
siRNA-based gene therapy program aiming to silence tau expression in the CNS.
SOD1-targeting siRNA gene therapy for ALS
Lead development candidate selected for a gene therapy program designed to silence SOD1 for the treatment of SOD1-linked amyotrophic lateral sclerosis; program advanced toward IND filing.
Vectorized anti-Aβ antibody gene therapy for Alzheimer’s disease (research)
Research program to express anti-amyloid antibodies via gene transfer to provide sustained CNS exposure.
Partnered gene therapy programs for rare and CNS diseases
Licensed or partnered programs targeting indications such as Friedreich’s ataxia, Gaucher disease/Parkinson’s disease, spinal muscular atrophy, Huntington’s disease, and other CNS disorders; includes capsid licensing to external developers.
Anti-tau antibody therapy for Alzheimer’s disease (development candidate)
Preclinical and IND-enabling development of an anti-tau biologic intended to modify disease processes in Alzheimer’s disease.
Tau-targeting siRNA gene therapy for Alzheimer’s disease
siRNA-based gene therapy program aiming to silence tau expression in the CNS.
SOD1-targeting siRNA gene therapy for ALS
Lead development candidate selected for a gene therapy program designed to silence SOD1 for the treatment of SOD1-linked amyotrophic lateral sclerosis; program advanced toward IND filing.
Vectorized anti-Aβ antibody gene therapy for Alzheimer’s disease (research)
Research program to express anti-amyloid antibodies via gene transfer to provide sustained CNS exposure.
Partnered gene therapy programs for rare and CNS diseases
Licensed or partnered programs targeting indications such as Friedreich’s ataxia, Gaucher disease/Parkinson’s disease, spinal muscular atrophy, Huntington’s disease, and other CNS disorders; includes capsid licensing to external developers.
Services
Partnering arrangements for co-development and licensing of gene therapy programs and capsid technologies for neurological diseases.
Partnering arrangements for co-development and licensing of gene therapy programs and capsid technologies for neurological diseases.
Expertise Areas
- Neurogenetic medicine development
- AAV capsid engineering for CNS delivery
- Receptor-mediated blood–brain barrier targeting
- Gene therapy construct design (siRNA and vectorized antibodies)
Key Technologies
- AAV capsid engineering
- Receptor-mediated BBB transport
- siRNA-mediated gene silencing
- Vectorized antibody gene therapy
News & Updates
Voyager CEO Alfred W. Sandrock Jr. will present at the conference.
Voyager has selected a lead candidate for its SOD1 gene therapy for ALS, with an IND filing expected in mid-2025.
Voyager announced its financial and operational results for Q3 2023, including progress on its gene therapy programs.
Voyager CEO Alfred W. Sandrock Jr. will present at the conference.
Voyager has selected a lead candidate for its SOD1 gene therapy for ALS, with an IND filing expected in mid-2025.
Voyager announced its financial and operational results for Q3 2023, including progress on its gene therapy programs.